Navigation Links
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Date:10/27/2008

Duramed to Launch First Lower-Dose, Extended-Cycle Oral Contraceptive for the Prevention of Pregnancy

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for LoSEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive. LoSEASONIQUE(R) is the first lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Under the LoSEASONIQUE(R) extended-cycle regimen, women take combination tablets containing 0.10 mg levonorgestrel/0.02 mg of ethinyl estradiol daily for 84 consecutive days, followed 0.01 mg ethinyl estradiol tablets for seven days. The regimen is designed to reduce the number of withdrawal bleeding periods from 13 to four per year. By contrast, the majority of oral contraceptive products currently available in the United States are based on a regimen of 21 treatment days, followed by seven days of placebo.

LoSEASONIQUE(R) will be shipped to trade customers and available by prescription to women in the first quarter of 2009. Duramed will initiate promotion to healthcare providers in early 2009 using its sales force and other marketing initiatives.

"As a leader in women's health, Duramed is committed to continuing to develop new products that provide women a choice as they discuss birth control options with their healthcare providers," said Fred Wilkinson, Duramed's Chief Executive Officer. "We're pleased that the FDA has approved LoSEASONIQUE(R) as a safe, effective new birth control option for U.S. women." '/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
4. FDA Approves Fougeras Clotrimazole Cream USP 1%
5. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
6. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
7. Signalife Board Approves Merger
8. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
11. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... This cutting ... Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the world’s first ... is in spec deep into the NIR range. Previous spectrophotometer calibration standards, such as ...
(Date:6/29/2015)... DIEGO , June 29, 2015 BioNano ... group of top research institutes, announced today that a ... Mount Sinai resulted in the creation of the first ... complementary single DNA molecule methods for sequencing and genome ... , provided the comprehensive analysis of the contiguous diploid ...
(Date:6/29/2015)... According to a new market research ... (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), by End ... Global Forecast to 2020", published by MarketsandMarkets, the global Aptamers ... $107.56 Million in 2015, at a CAGR of 17.89%. ... F igures spread through 125 ...
(Date:6/29/2015)... Elsevier , a world-leading ... services, today announced the highlights of its journal Impact ... Citation Reports® (JCR) published by Thomson Reuters, Elsevier saw ... to 2014, ahead of the aggregate across other journals. ... 62 subject categories, up from 61 in 2013. ...
Breaking Biology Technology:FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3
... , , , , , , ... , AUDIO: A team ... Click here for more information. , ... , , , , ...
... , SEATTLE, Nov. 20 Dendreon Corporation ... and Drug Administration (FDA) provided written acknowledgement that the Company,s ... complete response. The FDA has assigned a Prescription Drug ... which time it will respond to Dendreon,s amended BLA. ...
... , SEATTLE, Nov. 20 Cell Therapeutics, Inc. (CTI) (Nasdaq ... Appeals reversed a U.S. District Court order and ruled that CTI ... Lash Group, sending the case back to the District Court for ... former third-party reimbursement consultant for CTI,s product TRISENOX, in 2007 seeking ...
Cached Biology Technology:Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/29/2015)... , June 24, 2015 ... of the "Latin America Biomedical Sensors Market - ... offering. The Latin America Biomedical Sensors market ... CAGR of 2.04% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... announces the latest edition of an essential ... rapidly changing fields of clinical medicine. Covering novel viruses, ... informs scientists and health care professionals about all ... "Virology is currently one of the ...
... 2009The relationships between food, nutrition science, and health outcomes ... variation among individuals and populations is a new factor ... relationships. Hence, the rapidly emerging intersection of nutritional science ... a special issue of OMICS: A Journal of ...
... up a gas tank when the gasoline price hit close ... consumes fuel, which not only increases our vulnerability to foreign ... that will impact adverse change in climate and global warming. ... developing techniques that will lessen our monetary pain at the ...
Cached Biology News:New edition available for essential virology reference 2Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS 2Engineer devises ways to improve gas mileage 2Engineer devises ways to improve gas mileage 3
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Rad1 MAb (Clone 33)...
Biology Products: